638) being the next-most abundant product (2) . Aβ42 and Aβ40 tend to form oligomeric aggregates and fibrillar structures (3). Both peptides can be detected in amyloid plaques found in AD brains, but Aβ42 tends to form aggregates more rapidly, and is the majority species (2) . In peripheral blood, the major species is Aβ40 (4).
Aβ-binding autoantibodies are present in healthy humans, AD patients (5, 6) and pooled human IgG marketed as IVIG formulations (intravenously administered immunoglobulins; ref 7) . Phase 1 human clinical trials have suggested that infusion of pooled human IgG into the peripheral circulation may be useful in treating AD (7) . Similarly, intravenous administration of Aβ-binding monoclonal antibodies (Abs) of the IgG class to transgenic mice expressing human Aβ, which are frequently used as an experimental model of AD, clears amyloid plaques from the brain and improves cognitive performance (reviewed by refs 8,9) . The following mechanisms are thought to explain the amyloid-clearing effect of intravenously administered Aβ-binding IgGs: (a) Small amounts of the IgGs cross the bloodbrain barrier (BBB), bind Aβs in the brain, and microglial cells clear the resultant immune complexes by Fc-receptor mediated uptake (9) ; and (b) According to the 'peripheral sink' hypothesis (10) , Aβs can be cleared from the brain without the requirement for IgG entry into the brain. In this hypothesis peripheral Aβ-Ab binding perturbs the equilibrium between the peptide pools in the brain and periphery, thereby stimulating Aβ release from the brain. In principle, both mechanisms can be triggered by the same Ab.
Studies on human autoantibody preparations yielded the first empirical evidence that certain Abs can catalyze the hydrolysis of peptide bonds (11) . Abs with proteolytic activity can inactivate polypeptide antigens permanently, and a single catalyst molecule can hydrolyze multiple antigen molecules. This results in improved antigen inactivation by catalytic Abs compared to reversibly-binding Abs (which bind antigens stoichiometrically; e.g., 2 antigen molecules/IgG molecule) (12) . We reported previously the hydrolysis of Aβ40 by the cross-reactive light chain subunit of catalytic Abs to the neuropeptide vasoactive intestinal peptide (13) . Free light chain subunits of Abs are not found at appreciable levels in extracellular fluids. Moreover, light chains with catalytic activity in their free state frequently fail to express this activity when paired with the heavy chain subunit as components of intact Abs (14, 15) . It is not clear, therefore, whether Abs in their physiological structures can catalyze the hydrolysis of Aβ.
B lymphocytes synthesize structurally and functionally distinct classes of Abs at different stages of their life cycle. IgM class Abs are distinguished by the ability to catalyze the hydrolysis of model peptide substrates at rates substantially greater than IgGs produced at the later B cell differentiation stages after class switch recombination has occurred (16) . Improved cognitive performance in the Aβ-overexpressing mouse model of AD has been reported upon immunization with certain Aβ analogs that induce an Aβ-binding IgM response in peripheral blood without an appreciable IgG response (17) . In the present study, we examined the ability of monoclonal and polyclonal IgM preparations from humans to catalyze the hydrolysis of Aβ40. We report the properties of specific Aβ hydrolyzing IgMs in aged humans and AD patients, and we present alternative arguments supporting their beneficial versus deleterious roles.
MATERIALS AND METHODS

Antibodies. The panel of monoclonal human
IgMs purified from patients with Waldenström's macroglobulinemia has been described (ref 18; our  lab code #s 1718, 1801, 1809, 1810, 1812, 1813,  1814, 1816, 1817 and 1818) . Polyclonal IgM and IgG preparations were from sera obtained from human subjects of either sex without evidence of neurodegenerative or autoimmune disease (nonelderly subjects, 1 female and 5 males, 35±8 years old; elderly undemented subjects, 13 females and 12 males, 76±6 years) and from AD patients (11 females and 12 males, 76±6 years; ref 19) . The IgMs were purified by affinity chromatography on columns of immobilized Abs to human IgM, quantified by the bicinchoninic acid protein assay kit, and determined to be electrophoretically homogeneous by reducing SDS-electrophoresis and immunoblotting with goat anti-human IgM and anti-human IgG Abs (18) . Nominal molecular mass values were computed by comparison with by guest on November 7, 2017 http://www.jbc.org/ Downloaded from standard proteins (14-94 kDa; Amersham Biosciences). Denaturing gel filtration was on a Superose-6 FPLC gel filtration column in 6 M guanidine hydrochloride in PBS (10 mM sodium phosphate, 137 mM NaCl, 2.7 mM KCl containing 0.1 mM CHAPS adjusted to pH 6.5; ref. 16) . Column calibration was with thyroglobulin (660 kDa), IgG (150 kDa), and albumin (67 kDa). The IgM was renatured by dialysis against PBS.
Aβ proteolysis and binding. Synthetic Aβ40 (100 µM; American peptide, CA) was treated with 1,1,1,3,3,3-hexafluoro-2-propanol (Aldrich) to eliminate aggregates (3) and incubated at 37ºC with purified Abs in 0.1 ml 50 mM Tris-HCl, pH 7.7, 100 mM glycine containing 0.1 mM CHAPS (designated TG-CHAPS buffer). The reaction mixtures were fractionated by reversed-phase HPLC (RP-HPLC; Nova-Pak C18 3.9×150 mm column, Waters DELTA-600 system, 2487 UV/Vis detector; Milford, MA; linear gradient of 10-80% solvent B in 40 min; solvent A, 0.05% trifluoroacetic acid in water; solvent B, 0.05% trifluoroacetic acid in acetonitrile; 1 ml/min) with online electron spray ionization-mass spectrometry (ESI-MS; LCQ DECA XP plus, Thermo Electron, San Jose, CA; spray voltage 4.5 kV, heat capillary at 200°C; scan range m/z 400 to 2000). The zoomscan function and collision induced desorption function after ESI were utilized as needed (collision-energy value 35%). The reaction rates were computed from the area of the Aβ1-28 product peak interpolated from a standard curve constructed using increasing amounts of synthetic Aβ1-28. Apparent kinetic parameters were estimated by fitting hydrolysis rates observed at varying Aβ40 concentrations (3, 10, 30, and 100 μM) to the Michaelis-Menten equation
, where V max is the maximum velocity at saturating Aβ40 concentrations and K m is the concentration at which half maximal velocity was observed. Aβ40 hydrolysis in certain assays was determined using 125 I-Aβ40 as substrate as described previously (20) . Briefly, 125 I-Aβ40 was prepared using the chloramine-T method and purified by RP-HPLC (retention time 43.5 min; specific activity 2.2 Ci/μmol). The 125 I-Aβ40 (~0.1 nM, ~30000 cpm/tube) was treated with the Abs (0.1 ml, 37 °C) in TG-CHAPS buffer containing 0.1% (w/v) bovine serum albumin. One ml 5.5% trichloroacetic acid (TCA) was added, and the acid insoluble (intact peptide) and acid soluble (peptide fragments) fractions were separated by centrifugation (3000 rpm, 30 min). The acidsoluble radioactivity was counted by γ-spectrometry and corrected for background values measured in control assay tubes incubated in diluent without Abs (mean ± s.d., 18 ± 6%; n = 7 ).
Ab catalyzed hydrolysis of Glu-Ala-Arg-AMC [Boc-Glu(OBzl)-Ala-Arg with 7-aminomethylcoumarin linked to the C terminus; 0.2 mM, Peptides International, Louisville, KY] was measured in 96-well plates in TG-CHAPS buffer containing 0.5% DMSO at 37°C (16) . AMC release was determined by fluorometry (λem 470 nm; λex 360 nm). The synthesis of electrophilic hapten 1 (EP-hapten 1) employed as an inhibitor of catalysis has been described (21) . Hydrolysis of biotinylated proteins was determined by SDSelectrophoresis using peroxidase conjugated streptavidin to stain the proteins (18) . Aβ40 binding was determined by ELISA in 96-well microtiter plates (Maxisorp, Nunc). The plates were prepared by coating with streptavidin (10 µg/ml 100 mM sodium bicarbonate buffer, pH 9.3; 1 h, 37 °C; Sigma), blocking with 5% skim milk in PBS containing 0.025% Tween 20 (PBSTween), and treatment with biotinylated Aβ40 (4 µg/ml, 1 h, 37 °C; American Peptide). Thereupon, the wells were treated with the IgM for 2 hours in PBS-Tween containing 5% skim milk and bound IgM was measured using peroxidase conjugated goat anti-human IgM (µ chain specific, 1:500; Sigma; ref 18 26 ) was employed to determine neural cell death. Briefly, the cells were plated in 96-well polystyrene plates (0.1 ml/well; 20,000 cells/well), incubated for 24 h to allow attachment, and then cultured for 3 days with diluent, Aβ40 alone (0.4 µM), IgM alone (0.54 mg/ml) or Aβ40 (8 µM) previously incubated for 12 days with the IgM (0.54 mg/ml). Cell viability was determined using an MTT assay kit (CellTiter 96 Assay; Promega). Cell viability data are reported using the control diluent wells as reference (100%) after subtraction of the background A560 value observed in wells containing diluent without cells.
Atomic force microscopy. Peptide aggregates were visualized according to Dahlgren et al. (ref 3) using a NanoScope IIIa atomic force microscope (Digital Instruments, Santa Barbara, CA) equipped with a MultiMode head and an Eseries piezoceramic scanner (xy range 10 µm; tapping mode, silicon microcantilevers with 300-kHz resonant frequency and 42 Newton/meter spring constant; probe OMCL-AC160TS-W2, Olympus). The peptide-Ab mixture (10 µl) was spotted on freshly cleaved mica (Ted Pella, Inc., Redding, CA), incubated at room temperature for 5 min, washed with water, and dried under vacuum. Image data were acquired at scan rates between 1 and 2 Hz with drive amplitude and contact force kept to a minimum. At least three regions of the mica surface were examined to ensure that similar structures existed throughout the sample.
RESULTS
Aβ hydrolysis by monoclonal IgMs. We previously reported the proteolytic activity of monoclonal IgMs from patients with Waldenström's macroglobulinemia using model peptide substrates (16) . Here, the same panel of identically purified monoclonal IgMs was examined for the ability to cleave Aβ40. Treatment of Aβ40 with 2 monoclonal IgMs depleted the intact Aβ40 peak accompanied by appearance of peptide products absent in control reversed-phase HPLC chromatograms of the IgM alone or Aβ40 alone ( Table S1 ). We concluded that IgM Yvo cleaved the Lys28-Gly29 and Lys16-Leu17 bonds. From the HPLC product peak heights, the Lys28-Gly29 bond was the major cleavage site, and the Lys16-Leu17 bond, the minor cleavage site.
The C terminal Aβ17-40 fragment corresponding to minor cleavage (Lys16-Leu17 bond) was not detected, presumably due to loss on the HPLC column or precipitation prior to fractionation.
A product corresponding to Aβ1-28 was also identified by HPLC/electrospray ionization-MS following treatment of Aβ42 with IgM Yvo but not the non-hydrolytic IgM 1816 under the by guest on November 7, 2017 http://www.jbc.org/ Downloaded from conditions described in Fig 1, indicating hydrolysis of the Lys28-Gly29 bond. Accurate measurement of Aβ42 hydrolysis was not possible because of visible peptide aggregation prior to the HPLC procedure.
Aβ40 hydrolysis by IgM Yvo was saturable with progressively increasing peptide concentration and the observed rates were consistent with the Michaelis-Menten kinetics (r 2 = 0.94; Table 1 ). Over 25 hours, 0.6 µmol IgM Yvo cleaved 24 µmol Aβ40 in Fig. 1A , confirming the turnover capability of the IgM. Electrophilic phosphonate diesters are class-specific irreversible inhibitors of serine proteases (27) that inhibit IgM catalyzed hydrolysis of peptide-AMC substrates (16) . Hydrolysis of Glu-Ala-Arg-AMC by IgM Yvo was inhibited by Aβ40 ( Fig. 2A) (Fig. 2B) . The x-intercept of the plot was 10.2, compared to the theoretical value of 10 antigen combining sites per molecule IgM. The observed stoichiometry of 10.2 substrate molecules cleaved per molecule of IgM is inconsistent with the possibility of trace contamination as the explanation for catalysis, as only small amounts of the electrophilic phosphonate diester relative to the total IgM concentration should suffice to inhibit trace contaminants. Previously published control studies have indicated that the catalytic activity is retained in the Fab fragments of IgM Yvo and maintained at constant levels following successive purification steps (16) . These observations suggest that the catalytic activity is attributable to the IgM.
The presence of a serine protease-like catalytic triad in IgM Yvo has been inferred from its crystal structure (23). NMR studies have suggested a random coil conformation of the N-and C-termini of Aβ40 with a tendency to form α-helices at residues 15-24 and 28-36 (22). The peptide bonds hydrolyzed by IgM Yvo are located in these regions (Lys16-Leu17 and Lys28-Gly29). Alternate molecular models of Aβ14-24 or Aβ26-36 docked as helices with the V regions of the IgM were prepared (Fig. 3) . The models suggested the feasibility of close encounter between the putative Ser94L Oγ nucleophile and the carbonyl C atom of the two scissile peptide bonds (Lys16-Leu17 and Lys28-Gly29 bonds; observed interatomic distance, 3.8-4 Å). The docked complex of Aβ26-36 containing the major scissile bond is about 6 kcal/mol more advantageous energetically than the complex of Aβ14-24 containing the minor cleavage site. In both models, the buried Lys side chain at the scissile bonds (Lys16, Lys28) forms 3 hydrogen bonds with residues located in heavy chain variable domain complementarity determining regions (CDRs) 2 and 3 (Tyr52, Trp98 and Glu100a). These observations support the likelihood of nucleophilic attack by the IgM at the two peptide bonds, a prerequisite for polypeptide cleavage by serine proteases.
Peptide aggregation and toxicity. Aβ40 forms oligomeric and fibrillar structures upon prolonged incubation that can be visualized by atomic force microscopy (26, 28) . The numbers of oligomers (spherical particles with diameter 4-20 nm), protofibrils and short fibrils observed following Aβ40 treatment with catalytic IgM Yvo were lower than in the control reaction mixture of the peptide and noncatalytic IgM 1816 (respectively, by 72.1%, 75.1% and 83.1%; Fig. 4A ). Under these conditions, 99.9% of the available Aβ40 is predicted to be hydrolyzed by IgM Yvo (from the equation
]t) ), where P t is product concentration at time t (12 days) and the value of k is V max /K m , see Table 1 for V max and K m values). Aβ40 was present at 13-fold excess over the IgM in this experiment. No Aβ40 binding by the IgM was detected by ELISA (A490 < 0.1; 100 µg IgM/ml). Therefore, the observed effects of IgM Yvo can not be attributed Aβ40 binding.
The toxic effect of Aβ40 on neuronal cell lines maintained in culture has been reported (3,26). We studied the viability of SH-SY5Y neuronal cells following treatment with Aβ40 alone, Aβ40 pretreated for 12 days with IgM Yvo and IgM Yvo alone. The toxic effect of Aβ40 was reduced significantly in the presence of IgM Yvo ( Fig. 4B ; P<0.0001; Students t-test, unpaired). The IgM alone did not influence the level of cell viability.
Aβ40 hydrolysis by polyclonal Abs. We have described the preparation and purity of polyclonal IgMs from human sera that hydrolyze model peptide substrates and the HIV protein gp120 (16, 18) . In the present study, we applied the same methods to obtain electrophoretically homogeneous IgMs from the sera of elderly healthy subjects without dementia (n = 7). Six of the seven IgM preparations from these individuals hydrolyzed Aβ40, determined by RP-HPLC (Fig.  5A ). The levels of activity detected in the 6 IgM preparations varied over a 10-fold range. The IgM hydrolytic activity was saturable with increasing Aβ40 concentrations (see Table 1 for K m and V max values). Next, we compared the activity of pooled IgM from the elderly subjects (n = 7) and nonelderly adults (n = 6). The HPLC product profiles of Aβ40 treated with each polyclonal IgM preparation were essentially identical to the profile obtained by treating the peptide with the monoclonal IgM (see Fig. 1 ). The hydrolytic activity of IgM from the elderly group was greater than the IgM from the non-elderly group (P=0.035, n = 4 independent hydrolysis assays; Student's t-test for unpaired observations; Fig.  5B ).
Hydrolysis of the model peptide-AMC substrates by polyclonal Abs serves as an indicator of the overall catalytic activity (16) without regard to specificity for Aβ40. We compared the Aβ40 and Glu-Ala-Arg-AMC hydrolyzing activities of IgMs from 25 undemented, elderly humans. Aβ40 hydrolysis was measured using a small concentration of 125 I-Aβ40 mixed with excess albumin as an alternate substrate (respective concentrations, 0.1 nM and 14.7 µM). This minimizes the contribution of promiscuous antigen recognition. Intact and product Aβ peptides were separated by precipitation with TCA. The extent of peptide hydrolysis measured by this method was highly correlated with 125 I-Aβ40 hydrolysis determined by RP-HPLC (r 2 0.96; % hydrolysis observed at 0.054, 0.22 and 0.54 mg/ml IgM Yvo by the TCA precipitation method, respectively, 15.5, 35.2 and 65.1%; by the HPLC method, respectively, 4.7, 15.0 and 50.0%). Twenty two of the 25 IgM preparations studied displayed detectable 125 I-Aβ40 hydrolytic activity varying over a 118-fold range, with no activity detected in the remaining 3 IgM preparations (Fig. 5C ). All 25 IgM preparations displayed readily-detected GluAla-Arg-AMC hydrolysis. There was no correlation between the 125 I-Aβ40 and Glu-AlaArg-AMC hydrolyzing activities (r 0.01, P=0.67; Fig. 5C ). There is no evidence, therefore, that the varying Aβ hydrolyzing activity of IgMs from individual humans is due to variations in the level of non-selective catalytic Abs.
To evaluate disease association, we compared the hydrolysis of 125 I-Aβ40 by IgM preparations from 25 non-demented elderly individuals and 23 AD patients. IgMs from the AD group displayed superior hydrolytic activity (P<0.0001; MannWhitney U test and Student's t-test; both tests 2 tailed, unpaired; Fig. 6A ). There was no gender bias in the distribution of the catalytic activity (P>0.05; non-demented group, 13 females and 12 males; AD group, 11 females and 12 males). The HPLC product profile of Aβ40 treated with polyclonal IgM preparations from 4 AD subjects was essentially identical to the profile using IgM Yvo (see Fig. 1 ). A pooled IgM preparation from 5 AD patients with the greatest Aβ40 hydrolyzing activity (codes# 2037, 2039, 2041, 2043 and 2044) failed to hydrolyze biotinylated soluble epidermal growth factor receptor, albumin or ovalbumin determined by an electrophoresis assay (Fig. 6B) . It may be concluded that increased Aβ40 hydrolysis by IgM preparations from AD patients is not due to an increase of non-specific catalytic activity.
The possibility of interfering serum constituents was evaluated by treating Aβ40 (0.1 nM 125 I-Aβ40 mixed with 100 µM nonradioactive peptide) with the IgM (0.9 mg/ml; purified from pooled serum of the elderly group) in the presence of unfractionated serum (final serum concentration, 5%; pooled from the non-elderly group). The observed Aβ hydrolytic rate in the mixture was 83.8 ± 10 pmol/h/0.1 ml. In the control incubation with unfractionated serum alone (no purified IgM), the observed rate was 6.0 ± 0.1 pmol/h/0.1 ml. The difference, 77.8 pmol/h/0.1 ml, represents the activity attributable to the purified IgM. This value is close to the IgM activity without serum observed in Fig 5B ( 67.4 pmol/h/0.1 ml), suggesting that the IgM catalyzed reaction can proceed unimpeded in the presence of serum.
Trace protease contaminants could account for the observed catalytic activity if such contaminants bind the IgMs or the column matrix applied for affinity purification of the IgMs. In this case, the Aβ40 hydrolytic activities of identically purified IgMs from different human donors should be of . This is does not support the possibility of trace contaminants. As an additional test that the hydrolytic activity is attributable to the IgMs, pooled polyclonal IgM previously purified by affinity chromatography using anti-IgM antibody (non-demented group; n=6 subjects) was subjected to 2 cycles of sequential gel filtration in a solvent that dissociates noncovalently associated protein-protein complexes (6 M guanidine hydrochloride). As the polyclonal IgMs are mixtures of diverse Abs, charge separations can not be employed, and affinity chromatography followed by a mass-based separation is a suitable test for purity. A similar affinity chromatographysequential denaturing gel filtration protocol was applied in our previous studies to validate the hydrolysis of other peptide substrates by IgMs (16, 18) . In the present study, the highly purified 900 kDa IgM fraction from the second chromatography cycle (supplemental Fig S1) displayed detectable Aβ40 hydrolytic activity determined by RP-HPLC (68 pmol/h/mg IgM), and the product profile was essentially identical to that observed in Fig 1A. To our knowledge, there are no known conventional proteases with mass 900 kDa. The denaturing column conditions preclude the possibility of smaller adventitious proteases.
DISCUSSION
Soluble Aβ oligomers are recognized to impair neuronal function by altering the expression of memory-related receptors (29) , inducing aberrant neuronal responses to electrical stimulation (30) and inducing neural death (3,26). The major implications of the Aβ-specific catalytic IgMs reported in the present study concern their functional role and potential utility in AD immunotherapy. The beneficial effects of Aβ-binding autoantibodies of the IgG class found in the peripheral blood of non-demented humans have been discussed previously (reviewed by Geylis et (33) . Reduced free Aβ levels in the periphery due to the Aβ-binding reagents such as gelsolin and soluble lipoprotein receptors also induce increased Aβ efflux from the brain and decreased influx into the brain (34, 35) . The concentrations of Aβ40 and Aβ1-42 in blood are ~0.2 and ~0.05 ng/ml, respectively (4) . If IgM present in peripheral blood is assumed to express catalytic activity in vivo at the level in Table 1 , 92.8 % of Aβ40 present in the blood will be hydrolyzed after 5 days [corresponding to the halflife of IgM in blood (36); computed with assumptions stated in Table 1 legend]. Under the same assumptions, noncatalytic IgM will bind only 7.7 % of the Aβ in blood at equilibrium. As the peripheral and brain Aβ appear to exist in a state of equilibrium, these computations suggest the feasibility of depletion of brain Aβ as a consequence of peripheral IgM catalyzed Aβ hydrolysis.
Both major Aβ peptides, Aβ40 and Aβ42, form the soluble oligomeric aggregates thought to cause neurodegenerative effects. Aβ40 is the major product generated by APP processing via the β-and γ-secretase pathways, whereas Aβ42 is the more aggregogenic species. Aggregation of Aβ42 proceeds rapidly to the fibrillar stage, for which reason it was difficult to conduct controlled biochemical analysis of Aβ42 as a substrate for the catalytic IgMs. However, analyses of reaction mixtures containing Aβ42 indicated that the monoclonal catalytic IgM also hydrolyzes Aβ42 at the major cleavage site identified in Aβ40 (Lys28-Gly29; see Results). The catalytic monoclonal IgM inhibited Aβ40 aggregation and Aβ40 toxicity in cultured neuronal cells. No Aβ40 binding by the IgM was detected. Aβ40 was present in excess over the IgM in these experiments. We concluded that the observed effects are due to hydrolysis of Aβ40, and that the Aβ40 fragments generated by the IgM have a lesser tendency to form aggregates and kill the cells compared to Aβ40. These observations provide important support for further development by guest on November 7, 2017 http://www.jbc.org/ Downloaded from of catalytic Abs in ameliorating Aβ neuronal toxicity using engineered versions of the catalytic IgMs. Small Ab fragments such as single chain Fv constructs (Ab light and heavy chain variable domains linked by means of a short peptide) can be expected to enter the brain at least as readily as IgGs. Single chain Fv fragments that hydrolyze other polypeptides have been reported (37) , and preparing small catalytic homologs of Aβ hydrolyzing IgMs should be routine by modern Ab engineering protocols.
Abnormalities of the BBB in AD have been discussed (38) . Peripherally injected monoclonal IgGs can enter the CNS in the mouse AD model (39) . However, IgMs are even larger molecules than IgGs (900 vs 150 kDa), and it is debatable whether catalytic IgMs are present in the CNS at concentrations sufficient to degrade Aβ appreciably within the brain. A recent study using an AD mouse model reported that a peripherally administered Aβ-binding monoclonal IgM can cross the BBB and exert favorable effects in the brain (40) . However, the IgM concentrations in the CSF of non-demented humans and AD patients are no different, and the CSF IgM concentrations are very low (~0.0005-0.001 mg/ml, compared to blood levels of 2 mg/ml, ref 41) . If CSF IgM expresses catalytic activity equivalent to bloodborne IgM, only 0.01% of Aβ40 and Aβ42 present in CSF will undergo IgM-catalyzed hydrolysis in 5 days (computed as in the preceding paragraph; CSF Aβ40 and Aβ42 concentrations are ~2.7 and ~0.28 ng/ml, respectively; ref 4).
While there is consensus that elevated Aβ concentrations are deleterious, several studies have described the potentially favorable neurotrophic effects of lower Aβ concentrations (e.g., 42, 43 ). An excessively strong Aβ clearing effect of the Abs, therefore, may be accompanied by undesirable side effects.
Inflammatory and vascular side effects of Abs are also possible. IgG-Aβ immune complexes can bind Fcγ receptors expressed by microglial cells and induce the release of inflammatory mediators (44) . In mouse AD models, clearance of amyloid plaques from the brain parenchyma induced by Aβ-binding IgGs can be accompanied by Aβ deposition in the blood vessels and microhemorrhages (45, 46) . A monoclonal Aβ-binding IgG administered peripherally to AD patients produced abnormal magnetic resonance images suggestive of edema 3 . In another human trial, vaccination of AD patients with Aβ induced sterile meningoencephalitis in some recipients (47,48). Generation of Aβ-specific T lymphocytes is the suggested cause, but the involvement of the Abs remains open. Recent studies suggest that IgMs may also activate microglial cells via cellular Fcµ receptors (49) . This is not a concern if the IgMs are present only in trace amounts in the brain because of proscribed passage of peripheral IgM across the BBB and limited secretion by B cells resident in the CNS. Theoretically, catalytic Abs are predicted to exert undesirable effects at a lower level than conventional Aβ-binding IgGs. The hydrolytic reaction and release of Aβ fragments will reduce the longevity of the immune complexes, diminishing activation of inflammatory reactions via Fc receptor binding compared to stablybinding Abs. Similarly, provided the Aβ fragments generated by the Ab catalyzed hydrolytic reaction are less amyloidogenic than intact Aβ, the opportunity for amyloid redeposition in the blood vessels is reduced.
Previous studies on Aβ-binding IgG autoantibodies in the serum of AD patients have yielded opposing results. Some studies report decreased binding activity (5, 50) , and others, increased binding activity (6, 51) . The discrepancy may derive from the assay of free Ab concentrations in these studies (as opposed to total Ab concentrations that take into account the amount of Abs complexed to Aβ). We did not study Aβ binding by the polyclonal IgM preparations in the present report, as catalytic IgMs are not expected to form stable immune complexes detected in conventional binding assays. At first glance, the observed increase of Aβ hydrolyzing IgMs in AD patients could be viewed to imply a potential disease-causing role. However, this interpretation is difficult to sustain in regard to the hydrolytic function, as the Aβ peptides do not serve any known useful function. If peripheral Aβ clearance is sufficient to induce drainage of brain Aβ stores, the following testable predictions can be made for future studies. First, the clinical progression of AD may be slowed by the catalytic autoantibody production. Second, infusion of pooled polyclonal catalytic IgM preparations or monoclonal catalytic IgMs into the peripheral vasculature may offer a therapeutic benefit in AD with reduced potential for inflammatory and angiopathic side effects compared to the IgG preparations currently in clinical trials for AD immunotherapy. The idea of engineered and naturally occurring catalytic Abs with beneficial effects is not unprecedented. Naturally occurring catalytic IgMs are suggested to contribute in defense against HIV (18) and reduced catalytic IgGs are correlated with death in patients with bacterial sepsis (52) . Numerous other examples of catalytic Abs have been reported, including proteolytic Abs to autoantigens (53, 54) , allo-and xenoantigens (55, 56) and microbial antigens (15, 57) .
Certain structural features of Aβ that may favor the synthesis of catalytic IgMs are noteworthy. Antigens containing repeat epitopes can stimulate T cell-independent Ab responses limited to the IgM class (58) . From the perspective of B lymphocytes, Aβ aggregates represent arrays of repeat antigenic epitopes. This may help explain the observed catalytic IgM autoantibody response. The IgMs did not hydrolyze irrelevant polypeptides and they hydrolyzed Aβ40 in the presence of excess albumin. The evident selectivity for Aβ40 is typical of adaptively matured IgM variable domains that develop selective noncovalent antigen binding capability by gene recombination (59) and hypermutation mechanisms (60) . Ab proteolytic activity has been traced by site-directed mutagenesis (61) and crystallization (23) studies to Ab variable domain nucleophilic sites with topography similar to serine proteases. The putative catalytic site of IgM Yvo contains an intramolecular hydrogen bonding network that imparts nucleophilic reactivity to Ser95 located in the light chain subunit (23). The feasibility of Aβ40 hydrolysis at this site is supported by our molecular modeling studies suggesting close proximity between the IgM nucleophilic Ser95 of the IgM light chain subunit and the Aβ40 scissile bonds (Lys28-Gly29 and Lys16-Leu17). The phosphonate diester found to inhibit IgM Yvo catalysis (Fig 2) is designed to mimic the electrophilic reactivity of peptide bond carbonyl groups. By virtue of its strong electrophilic reactivity, the phosphonate binds covalently to protein nucleophilic sites and inhibits their catalytic activity (27, 37) . We have previously reported the induction of Abs with enhanced nucleophilic and proteolytic activity by immunization with polypeptide analogs containing the electrophilic phosphonates (62, 63) . Interestingly, trypsin, a serine protease with a nucleophilic catalytic site, forms irreversible complexes with Aβ devoid of exogenously introduced electrophiles (64) . Aβ also inhibits the catalytic activity of trypsin (65). From these findings, it may be inferred that Aβ contains an unusually strong electrophilic group that can interact with enzymatic nucleophiles. The chemical identity of the electrophile remains to be determined. The evident electrophilicity of Aβ may induce strengthened nucleophilic and proteolytic activity over the course of adaptive maturation of the Ab response to antigens, helping explain our observations of increased catalytic IgMs in aged humans and AD patients.
In summary, our studies suggest the existence of beneficial Aβ40 hydrolyzing IgM class autoantibodies. The deleterious effects of the catalytic IgMs may be lower than IgG class Aβ-binding IgGs. These considerations support further examination of catalytic Abs as natural protective mediators and as reagents that could be developed for immunotherapy of AD. Table 1 . Apparent kinetics parameters for Aβ40 hydrolysis by monoclonal IgM Yvo and pooled polyclonal IgM from elderly non-demented human subjects. Reaction rates were measured by RP-HPLC following incubation of increasing Aβ40 (3-100 µM) with IgM Yvo (0.22 mg/ml) or polyclonal IgM (0.026 mg/ml, pooled from 6 subjects). Kinetic constants were obtained from non-linear regression fits to the Michaelis-Menten equation (r for IgM Yvo and polyclonal IgM, respectively, 0.97 and 0.94, respectively). 
TABLE
Antibody
